A 340B hospital is a hospital that participates in the federal 340B Drug Pricing Program, which requires pharmaceutical manufacturers to sell outpatient drugs to qualifying hospitals at significantly reduced prices. The program takes its name from Section 340B of the Public Health Service Act, and it’s designed to help hospitals that serve a high proportion of low-income or uninsured patients stretch their resources further. As of 2023, more than 2,600 hospitals were enrolled in the program, up from just 591 in 2005.
How the 340B Program Works
The core idea is straightforward: drug manufacturers that want their products covered by Medicaid must agree to sell those same drugs at steep discounts to eligible hospitals and other healthcare organizations (called “covered entities” in the law). The discounted price a hospital pays has a ceiling calculated by taking the average price the manufacturer charges and subtracting a rebate amount. In practice, this means 340B hospitals can purchase certain outpatient medications at prices well below what a typical hospital or pharmacy would pay.
Only outpatient drugs are covered. Medications administered during an inpatient hospital stay don’t fall under 340B pricing. The program covers a wide range of prescriptions, from cancer treatments and HIV medications to common chronic disease drugs, as long as they are dispensed on an outpatient basis.
Which Hospitals Qualify
Not every hospital can become a 340B hospital. The program targets facilities that serve vulnerable populations, and eligibility is limited to specific categories. The most common type is the disproportionate share hospital (DSH), which is a hospital where a high percentage of patients are on Medicaid or are uninsured. These hospitals must meet a specific threshold for their “DSH adjustment percentage,” a Medicare metric that reflects how much low-income care they provide.
Beyond DSH hospitals, several other hospital types can qualify:
- Critical access hospitals: Small, rural hospitals designated by Medicare because they serve geographically isolated communities.
- Sole community hospitals: Facilities that are the only hospital reasonably available to residents in their area.
- Children’s hospitals: Freestanding hospitals that primarily treat pediatric patients.
- Freestanding cancer hospitals: Specialty hospitals focused on oncology care.
Hospitals aren’t the only entities that qualify. Federally qualified health centers, Ryan White HIV/AIDS clinics, and certain other safety-net providers are also eligible. But when people refer to a “340B hospital,” they’re typically talking about a hospital in one of the categories above.
What Hospitals Do With the Savings
Here’s something that surprises many people: there is no federal requirement that 340B hospitals pass the drug discounts directly to patients. A hospital buys the drug at the 340B price but can bill the patient’s insurance (or the patient themselves) at a higher rate. The difference between the discounted purchase price and the reimbursement creates a financial margin the hospital keeps.
The intent behind this setup is that hospitals reinvest those savings into patient care, particularly services for uninsured and underinsured populations. Many 340B hospitals use the revenue to fund charity care, expand clinic hours, offer free medications to patients who can’t afford them, or keep rural facilities open. However, how the savings are spent is largely up to each hospital. This lack of specific spending requirements has become one of the program’s most debated features, with critics arguing that some hospitals use the margins to boost their bottom line rather than expand access to care.
Rules 340B Hospitals Must Follow
While hospitals have flexibility in spending their savings, they face strict compliance rules on the purchasing side. Two prohibitions are central to the program. The first is the ban on “diversion,” meaning a hospital cannot provide 340B-priced drugs to individuals who are not patients of that hospital. The drug must be prescribed by a provider at the covered entity for a patient who receives care there. The second is the prohibition on “duplicate discounts,” which prevents a hospital from getting both the 340B discount on a drug purchase and a Medicaid rebate on the same drug. Essentially, the manufacturer shouldn’t be discounting the same pill twice.
HRSA, the federal agency that oversees the program, conducts audits to verify hospitals are following these rules. Audits examine whether the hospital still meets eligibility requirements, whether drugs are going to legitimate patients, and whether duplicate discounts are being avoided. Hospitals found out of compliance can face corrective action or removal from the program.
There’s also a notable restriction for certain hospital types. Disproportionate share hospitals, freestanding cancer hospitals, and children’s hospitals are prohibited from using group purchasing organizations for their covered outpatient drugs. This means they must purchase 340B drugs directly rather than through buying cooperatives that other hospitals commonly use to negotiate volume discounts.
Why 340B Hospitals Are Controversial
The rapid growth of the program has fueled ongoing debate. The number of participating hospitals more than quadrupled between 2005 and 2023, and many of those newer participants are large health systems that have acquired physician practices and outpatient clinics, expanding the reach of their 340B purchasing. Pharmaceutical manufacturers argue this growth has gone far beyond the program’s original safety-net mission, allowing financially healthy hospitals to profit from discounts meant to help the poorest patients.
Supporters counter that the savings are essential for hospitals operating on thin margins in underserved communities. For a rural critical access hospital or an urban safety-net facility, 340B revenue can mean the difference between keeping a pharmacy open and closing it. The tension between these perspectives has led to litigation, proposed legislation, and ongoing regulatory changes that continue to reshape how the program operates.
If you’re a patient at a 340B hospital, the designation primarily affects what happens behind the scenes in the hospital’s pharmacy purchasing. You may benefit indirectly through expanded services, charity care programs, or patient assistance programs funded by 340B savings. Whether you’ll see a direct discount on your prescription depends entirely on that hospital’s policies, not on any federal mandate.